Breakthrough for AlzeCure in the development of drugs for nerve pain

AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.

New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.

– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.

AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.

More on the new study.

Published On: 2 June 2023

  • National conference with a focus on ATMP

    The national conference ATMP Sweden 2022 Stockholm takes place on 7-8 November. The conference begins with a half-day of seminar and study visit in Flemingsberg.

  • Lab facilities where businesses can grow

    A Working Lab, (AWL), has now opened its doors in Flemingsberg. The site offers generous lab spaces in various sizes to help more businesses grow in a vibrant life science environment.

  • Elicera Therapeutics develops new cancer treatment with help of advanced cell lab in Flemingsberg

    Uppsala-based Elicera Therapeutics is using the Pre-GMP core facility at Vecura in Flemingsberg as a first step in a study aimed at creating a new treatment for lymph node cancer.

  • Flemingsberg set to become home to Alfa Laval’s future innovations

    The opening of Alfa Laval’s new development and innovation centre in Flemingsberg in 2025 will also see the launch of an exciting new technology. Ground was recently broken for the centre, which will accommodate around 700 employees.

  • EU’s first innovation hub to be run from Flemingsberg

    Health Data Sweden (HDS) will be the first among the EU’s new digital innovation hubs. The initiative is managed by Sebastiaan Meijer, Deputy Head of School at KTH in Flemingsberg.